SCHEMBL19725262

SCHEMBL19725262

CCOC(=O)/C(Cl)=N/Nc1ccc(N)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ KYAT1 Q16773 5/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ ATM Q13315 2/20 0.49
▸ LMNA P02545 4/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ GAA P10253 5/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ALOX12 P18054 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ ABCB1 P08183 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11767611 0.88 KYAT1 (0.60) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL16730420 0.88 KYAT1 (0.60) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL11767616 0.88 KYAT1 (0.60) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL3560757 0.86 MEN1 (0.65) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL16361794 0.86 MEN1 (0.65) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL3560755 0.86 MEN1 (0.65) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL10410691 0.85 MAPT (0.59) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL19661582 0.85 KYAT1 (0.62) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL10410692 0.85 MAPT (0.59) MEN1KMT2AKYAT1NPSR1ATM
SCHEMBL12442232 0.85 MAPT (0.59) MEN1KMT2AKYAT1NPSR1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208036-B2 Process for the preparation of Apixaban and intermediates thereof UNICHEM LABORATORIES LIMITED (IN) 2019-02-19 — — US disclosed
US-20170362232-A1 PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF UNICHEM LAB LTD (IN) 2017-12-21 — — US disclosed
US-20170362232-A1 PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF UNICHEM LAB LTD (IN) 2017-12-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208036-B2 Process for the preparation of Apixaban and intermediates thereof HAX1, CYP4X1, HTRA1 MEN1 1657/4885KMT2A 3158/4885KYAT1 3854/4885
US-20170362232-A1 PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF HAX1, CYP4X1, HTRA1 MEN1 1657/4885KMT2A 3158/4885KYAT1 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback